CYP2D6 and pharmacogenomics: Where does future research need to focus? Part 1: Technical aspects

Pharmacogenomics

Volumn 15, Issue 4, 2014, Pages 407-410

  Gaedigk, Andrea ^a   Leeder, J Steven ^a  

^a UNIVERSITY OF MISSOURI KANSAS CITY SCHOOL OF MEDICINE   (United States)

Author keywords

clinical implementation; CPIC; CYP2D6; cytochrome P450; drug metabolizing enzymes; genetic variation; pharmacogenetics

Indexed keywords

CYTOCHROME P450 2D6; TRICYCLIC ANTIDEPRESSANT AGENT;

COPY NUMBER VARIATION; CYP2D6 GENE; DRUG ABSORPTION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG METABOLISM; EDITORIAL; GENE ASSIGNMENT; GENE FREQUENCY; GENE LOCUS; GENE REARRANGEMENT; GENETIC ANALYSIS; GENETIC VARIABILITY; GENOTYPE PHENOTYPE CORRELATION; HUMAN; INDEL MUTATION; PHARMACOGENOMICS; SINGLE NUCLEOTIDE POLYMORPHISM; UPREGULATION; ALLELE; GENETICS; PHARMACOGENETICS; PROCEDURES; RESEARCH;

ALLELES; CYTOCHROME P-450 CYP2D6; HUMANS; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; RESEARCH;

EID: 84896377326     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.14.28     Document Type: Editorial

References (20)

1. Zhou SF. Polymorphism of human cytochrome P4502D6 and its clinical signifcance: part I. Clin. Pharmacokinet. 48(11), 689-723 (2009).
2. Zhou SF. Polymorphism of human cytochrome P4502D6 and its clinical signifcance: part II. Clin. Pharmacokinet. 48(12), 761-804 (2009).
3. Gaedigk A. Complexities of CYP2D6 gene analysis and interpretation. Int. Rev. Psychiatry 25(5), 534-553 (2013).
4. Gaedigk A, Twist GP, Leeder JS. CYP2D6, SULT1A1 and UGT2B17 copy number variation: quantitative detection by multiplex PCR. Pharmacogenomics 13(1), 91-111 (2012).
5. Gaedigk A, Ndjountche L, Divakaran K et al. Cytochrome P4502D6 (CYP2D6) gene locus heterogeneity: characterization of gene duplication events. Clin. Pharmacol. Ther. 81(2), 242-251 (2007).
6. Gaedigk A, Jaime LK, Bertino JS Jr et al. Identifcation of novel CYP2D7-2D6 hybrids: non-functional and functional variants. Front. Pharmacol. 1, 121 (2010).
7. Sim SC, Daly AK, Gaedigk A. CYP2D6 update: revised nomenclature for CYP2D7/2D6 hybrid genes. Pharmacogenet. Genomics 22(9), 692-694 (2012).
8. Gaedigk A, Fuhr U, Johnson C, Berard LA, Bradford D, Leeder JS. CYP2D7-2D6 hybrid tandems: identifcation of novel CYP2D6 duplication arrangements and implications for phenotype prediction. Pharmacogenomics 11(1), 43-53 (2010).
9. Kramer WE, Walker DL, O'Kane DJ et al. CYP2D6: novel genomic structures and alleles. Pharmacogenet. Genomics 19(10), 813-822 (2009).
10. Sim SC, Ingelman-Sundberg M. Update on Allele Nomenclature for Human Cytochromes P450 and the Human Cytochrome P450 Allele (CYP-Allele) Nomenclature Database. Methods Mol. Biol. 987, 251-259 (2013).
11. Hicks JK, Swen JJ, Gaedigk A. Challenges in CYP2D6 phenotype assignment from genotype data: a critical assessment and call for standardization. Curr. Drug Metab. doi:10.2174/1389200215666140202215316 (2014) (Epub ahead of print).
12. Gaedigk A, Simon SD, Pearce RE, Bradford LD, Kennedy MJ, Leeder JS. The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype. Clin. Pharmacol. Ther. 83(2), 234-242 (2008).
13. Steimer W, Zopf K, von Amelunxen S et al. Allele-specifc change of concentration and functional gene dose for the prediction of steady-state serum concentrations of amitriptyline and nortriptyline in CYP2C19 and CYP2D6 extensive and intermediate metabolizers. Clin. Chem. 50(9), 1623-1633 (2004).
14. Gaedigk A, Riffel AK, Garcia Berrocal B, Garcia-Solaesa V, Davila I, Isidoro-Garcia M. Characterization of a complex CYP2D6 genotype that caused an AmpliChip CYP 450 Test ® no-call in the clinical setting. Clin. Chem. Lab. Med. doi:10.1515/cclm-2013-0943 (2014) (Epub ahead of print).
15. Gaedigk A, Isidoro-Garcia M, Pearce RE et al. Discovery of the nonfunctional CYP2D6*31 allele in Spanish, Puerto Rican, and US Hispanic populations. Eur. J. Clin. Pharmacol. 66(9), 859-864 (2010).
16. Crews KR, Gaedigk A, Dunnenberger HM et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for cytochrome P4502D6 (CYP2D6) genotype and codeine therapy: 2014 update. Clin. Pharmacol. Ther. doi:10.1038/clpt.2013.254 (2014) (Epub ahead of print).
17. Hicks JK, Swen JJ, Thorn CF et al. Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants. Clin. Pharmacol. Ther. 93(5), 402-408 (2013).
18. Bustin SA, Benes V, Garson J et al. The need for transparency and good practices in the qPCR literature. Nat. Methods 10 (11), 1063-1067 (2013).
19. Wang D, Poi MJ, Sun X, Gaedigk A, Leeder JS, Sadee W. Common CYP2D6 polymorphisms affecting alternative splicing and transcription: long-range haplotypes with two regulatory variants modulate CYP2D6 activity. Hum. Mol. Genet. 23(1), 268-278 (2013).
20. Ramamoorthy A, Li L, Gaedigk A et al. In silico and in vitro identifcation of microRNAs that regulate hepatic nuclear factor 4alpha expression. Drug metabolism and disposition: the biological fate of chemicals. Drug Metab. Dispos. 40(4), 726-733 (2012).